Publish date: 3 July 2023
We have been supporting a University of Oxford study called Prevalence of Pathogenic Antibodies in Psychosis (PPIP) by acting as one of the sites recruiting potential participants. The PPIP study aims to see if psychosis in some patients could be triggered by an autoimmune response. The study uses blood tests to identify people who are carrying specific antibodies. Participants who are found to have this response are then referred to a connected SINAPPS2 study, which was featured last month in The Guardian. This aims to test different treatments for people with anti-neuronal antibodies.
Kelly Palethorpe, Registered Clinical Research Practitioner said:
“It is really exciting to be part of such important research. It is a great opportunity for service users to have this test, especially if they are at the beginning on their journey with Early Intervention in Psychosis (EIP) services to be able to rule out any autoimmune causes. It would be good to see this test become standardised in the NHS for everyone. As the PPIP study feeds into such important work for the SINAPPS trial, it is fantastic to be a part of this."